SmithKline Beecham Consumer Healthcare (SBCH) has reported satisfactory financial growth over the last three years. After the acquisition of Maltova and Viva, the company became the leader in the health food drink market. It enjoys a market share of over 70% with its leading brands Horlicks and Boost.
The sheen of SBCH has not dimmed even during the slowdown in the economy and multiplying competition. Competition in the market for malted beverages failed to make a dent in the company’s markets share. In the past 3 years, SBCH’s profits have grown at a compounded annual growth rate (CAGR) of 21.6% while turnover witnessed a CAGR of 12.7%. The company’s profit margins are highest in the industry.
Year ended December 31
Profit Before Tax
Profit After Tax
Operating profit margins
Tax / PBT
Net profit margins
Cash EPS (Rs)
*9m – Nine months
However, during the third quarter ended September 2000, SBCH’s profit growth was affected by higher raw material prices (milk powder and milk fluid) and increase in promotional expenditure. The company’s excellent working capital management has enabled it to maintain its operating margins at the current level despite of increase in key costs.
SBCH has amongst the lowest ad spent to sales ratio in the industry. The interesting fact to note is that during the past five years its sales grew at a faster rate than the growth in the advertising expenses. This is remarkable in the scenario of stiff competition where the companies are forced to spend more on promotional expenses in order to boost sales volumes.
Sales outperforms ad spends
5 yrs Advt. Exps CAGR
5 yrs. Sales CAGR
Advt. Exps as a % to sales
At the current market price of Rs 417, SBCH is trading at a P/E of 17 times its December 2000 projected earnings with a market cap to sales ratio of 2.2 times. The reasons for the company’s lower valuations compared to its peers in the industry are concerns about its parent’s 100% subsidiary. This subsidiary owns the leading oral care brand ‘Aquafresh’ and anti allergic brand ‘Crocin’. Also the fact that its parent imposed a 3.5% royalty on sales for the use of its technology has not gone down well with the investors.
The investor community is also worried about the future of SBCH in India in light of the parent’s merger with Glaxo worldwide. In India Glaxo is known for its pharma focus and as such there is uncertainty on what it decides to do with SBCH. However, if any of the major FMCG companies like HLL, Nestle or Cadbury were to acquire SBCH from Glaxo, the stock could see a re-rating.
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407